Americas · Regional markets · Financial Post
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the…
Read the full article on Financial Post Sign in to saveMarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (financialpost.com)
